Sun Pharmaceutical Industries Limited
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sun Pharmaceutical Industries Limited sits in the top decile of US sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count).
Sun Pharmaceutical Industries Limited: 38 sponsored US clinical trials, 4 recruiting.
Sun Pharmaceutical Industries Limited sponsors 38 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 26 completed. 22 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Active Psoriatic Arthritis, with 3 trials.
Top-decile sponsor footprint
Sun Pharmaceutical Industries Limited ranks in the top decile of sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
26 of 29 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
38 total, page 1 of 1
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
NCT07385547
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
NCT07282743
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
NCT05422911
Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
NCT03992729
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
NCT06425900
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
NCT04314531
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
NCT03997786
A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients
NCT06415279
A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
NCT06415292
A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne
NCT06336629
A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne
NCT06336603
A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
NCT06415305
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
NCT04684485
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
NCT03897075
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
NCT04566666
Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
NCT04506463
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544
Effect of Cequa™ in Subjects With Dry Eye Disease
NCT04357795
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
NCT03718299
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
NCT03897088
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
NCT03528577
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
NCT03552276
Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
NCT01543490
Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
NCT03192137
2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
NCT03192150
Efficacy and Safety Study of SUNPG1622
NCT02980705
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
NCT03245385
Efficacy and Safety Study of SUNPG1623
NCT02980692
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
NCT03212963
A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02737332
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT02688556
ABSORICA in Patients With Severe Recalcitrant Nodular Acne
NCT02457520
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT02254265
Bio-equivalence Study Between SAPHRIS and Asenapine
NCT01948024
Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis
NCT01408082
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
NCT01699022
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 12 |
| Phase 3 | 12 |
| Phase 4 | 10 |
What is open in the Sun Pharmaceutical Industries Limited pipeline
4 recruiting of 38 indexed (11% open); 26 completed (68%).
Phase mix: 22 late (III/IV) vs 15 early (I/II) (balanced across stages).
Top condition: Active Psoriatic Arthritis (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sun Pharmaceutical Industries Limited: open-pipeline peers nationwide
Peers matched on 38 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Sun Pharmaceutical Industries Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 38 trials (± recruiting share)
- Acerta Pharma · 38 trials · 0% recruiting
- Astex Pharmaceuticals · 38 trials · 0% recruiting
- Corewell Health West · 38 trials · 11% recruiting
- DePuy Orthopaedics · 38 trials · 5% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Bastyr University · 11% recruiting · 19 trials
- Ethicon · 11% recruiting · 38 trials
- Rowan University · 11% recruiting · 19 trials
- Saint John's Cancer Institute · 11% recruiting · 19 trials
Related
What to do with this Sun Pharmaceutical Industries Limited page
38 registered trials is a research-attention snapshot, not an endorsement of Sun Pharmaceutical Industries Limited or any single study.
- 4 of Sun Pharmaceutical Industries Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Active Psoriatic Arthritis is the condition Sun Pharmaceutical Industries Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Active Psoriatic Arthritis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sun Pharmaceutical Industries Limited pipeline card: 38 registered trials from official public datasets.Report a data error.